南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停
南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停
分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

阻断m6Am甲基转移酶PCIF1,可释放STAT1介导的Th1免疫反应,从而增强癌症免疫疗效。

Blocking the m6Am methyltransferase PCIF1 releases STAT1-mediated Th1 immunity to potentiate cancer immunotherapy

Huang Jiansong, Zhou Jing, Liu Xiao, Liu Xiaoxu, Xiao Ye, Li Kai, Ding Chenbo, Cai Xuemin, Mao Wenli, Xu Changfen, Kong Yuxin, Deng Yu, Song Xiaohan, Yang Mei, Du Daohai, Guo Siqi, Chen Kaixian, Luo

Journal:Nature Communications

IF:18.1

DOI:10.1038/s41467-026-75269-1

PMID:

Published:2026-07-22

research field:肿瘤学分子生物学药理学肺科学

Abstract

Naïve T cells maintain a delicate balance between quiescence and rapid activation, which involves multiple layers of regulation beyond transcription. Here, we identify the RNA modification N6,2’-O-dimethyladenosine (m 6 Am) and its methyltransferase PCIF1 as critical enforcers of T cell quiescence. During CD4 + T cell activation, m 6 Am levels are dynamically downregulated. T-cell-specific PCIF1 knockout (cKO) mice exhibit potent tumor suppression, driven by enhanced Th1 differentiation and subsequent amplification of NK cell cytotoxicity. Mechanistically, PCIF1 represses STAT1 translation via m 6 Am modification of its mRNA, thereby constraining Th1 commitment. Activation-induced PCIF1 downregulation releases this translational brake, enabling rapid Th1 polarization. Crucially, we identify Suramin as a pharmacological PCIF1 inhibitor that disrupts m 6 Am modification, boosts Th1 responses, and suppresses tumor growth. Our findings establish the PCIF1-m 6 Am-STAT1 axis as a translational checkpoint governing T cell differentiation and suggest that targeting PCIF1 represents a potential strategy for tumor immunotherapy.

本文使用的Yeasen产品

产品应用
购物车
客服
转染试用